- Investing Ideas
- /
- Mexican Pharmaceuticals & Biotech Potentially Undervalued Companies
Mexican Pharmaceuticals & Biotech Potentially Undervalued Companies
UPDATED Apr 21, 2024
Companies with a Value score of at least 3, ordered by Value score
61 companies
| Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | ||
|---|---|---|---|---|---|---|---|---|---|---|
LAB B | Mex$15.06 | -0.3% | 1.6% | Mex$14.0b | Mex$21.03 | PE13.6x | E27.1% | 5.2% | ||
EXAS * | US$1,141.00 | 0% | n/a | US$11.1b | US$1,670.80 | PS4.4x | E61.9% | n/a | ||
INDV N | UK£314.49 | -51.3% | -51.3% | UK£1.9b | UK£478.88 | PE14.1x | E14.4% | 0% | ||
GILD * | US$1,129.86 | 0% | -27.4% | US$83.2b | US$1,442.76 | PE14.7x | E10.0% | 4.6% | ||
BIIB * | US$3,320.00 | -5.8% | -37.1% | US$28.3b | US$4,967.32 | PE24.3x | E18.2% | n/a | ||
1093 N | HK$15.69 | 0% | -27.0% | HK$69.4b | HK$25.29 | PE10.4x | E1.4% | 4.7% | ||
RARE * | US$751.98 | 0% | 5.3% | US$4.2b | US$1,337.13 | PS9.6x | E48.2% | n/a | ||
JNJ * | US$2,530.00 | 3.1% | -13.4% | US$356.4b | US$2,951.08 | PE18.6x | E5.1% | 3.4% | ||
NVAX * | US$69.05 | 0% | -52.4% | US$555.6m | US$267.85 | PE-1x | E88.9% | n/a | ||
OGN * | US$299.00 | 0% | n/a | US$4.6b | US$360.75 | PE4.5x | E3.8% | 6.3% | ||
REGN * | US$15,326.56 | -3.0% | 5.1% | US$96.4b | US$17,699.70 | PE24.4x | E10.9% | n/a | ||
INCY * | US$986.00 | 0% | n/a | US$11.8b | US$1,425.34 | PE19.7x | E20.1% | n/a | ||
GSK1 N | UK£357.35 | 0% | n/a | UK£65.3b | UK£448.26 | PE13.3x | E9.4% | 3.6% | ||
PRGO N | US$686.00 | 0% | -3.8% | US$4.9b | US$902.68 | PS1.1x | S3.9% | 3.0% | ||
HALO * | US$680.00 | 0% | 0.04% | US$5.2b | US$873.74 | PE20.5x | E24.1% | n/a | ||
BGNE N | US$2,858.16 | 0% | n/a | US$14.0b | US$5,727.85 | PS5.7x | E56.2% | n/a | ||
VTRS * | US$196.05 | 0% | 18.1% | US$13.4b | US$216.01 | PE244.2x | E16.0% | 4.3% | ||
ELAN * | US$479.28 | 0% | 0% | US$4.6b | US$675.27 | PS1x | E35.9% | n/a | ||
MRNA * | US$1,750.00 | 1.0% | -30.0% | US$38.8b | US$2,317.56 | PS5.7x | E56.0% | n/a | ||
IFRX N | US$27.00 | 0% | n/a | US$79.5m | US$159.62 | PS1182.8x | E26.5% | n/a | ||
TEVA N | US$226.78 | -2.3% | 50.2% | US$14.6b | US$277.50 | PB1.9x | E32.1% | 0% | ||
IPN N | €1,936.56 | n/a | n/a | €9.0b | €2,226.45 | PE14.5x | E6.0% | 1.1% | ||
RPRX N | US$482.00 | 0% | n/a | US$16.8b | US$777.09 | PE11.1x | E6.0% | 3.0% | ||
ACAD * | US$509.00 | 0% | 60.5% | US$3.8b | US$679.54 | PS7x | E61.6% | n/a |